2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Joseph Gligorov, MD, PhD, discusses potential challenges of utilizing PARP inhibitors in triple-negative breast cancer.
Joseph Gligorov, MD, PhD, head, Breast Cancer Expert Center, Tenon Hospital, Paris, France, discusses potential challenges of utilizing PARP inhibitors in triple-negative breast cancer (TNBC).
PARP inhibitors have demonstrated robust benefits in disease control and progression-free survival in patients with TNBC, Gligorov says. However, data have not demonstrated a clear overall survival benefit with PARP inhibitors in this setting.
Additionally, some PARP inhibitors appear to have increased efficacy when combined with chemotherapy, but combination therapy may not be feasible, explains Gligorov.
Finally, PARP inhibitors can cause toxicities, including fatigue, nausea, vomiting, and hematologic events, which could limit their utility in some clinical settings, Gligorov concludes.